metaPreg - Primidone (All indications) during pregnancy

Primidone (All indications)

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	2.74 [1.43, 5.24]	0%	10 studies	49,650	161	low	ROB	4.92 [2.22; .]
Major congenital malformations	2.45 [1.08, 5.52]	9%	8 studies	49,633	122	not evaluable	ROB	4.33 [1.38; .]
Minor congenital malformations	3.46 [0.38, 31.70]	0%	2 studies	12	33	not evaluable	ROB	-
Neural Tube Defects	1.01 [0.06, 17.08]	0%	2 studies	1	41	not evaluable	ROB	-
8 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Small for gestational age (weight)	4.47 [0.14, 140.06]	56%	2 studies	599	21	not evaluable	ROB	-
Preterm (< 37 weeks)	6.23 [0.60, 64.99]	70%	2 studies	391	34	not evaluable	ROB	-
1 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
3 non statistically significant endpoints reported in only one study
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
1 non statistically significant endpoints reported in only one study
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Neuro-developmental disorders (as a whole)	2.15 [0.15, 30.90]	0%	2 studies	4	4	not evaluable	ROB	-
3 non statistically significant endpoints reported in only one study